Study of Guanfacine and Methylphenidate for the Treatment of Hyperactivity in Pervasive Developmental Disorder (PDD)
Current Opportunities to Participate in Autism Research at UCLA
One of the fundamental goals of the UCLA Center for Autism Research and Treatment (CART) is to provide a strong, collaborative environment for both basic and applied autism research. The UCLA CART fosters integration of the clinical, imaging, genetic, and basic science research into autism for which UCLA is renowned. Scientists at the UCLA CART include leading experts in autism genetics, brain imaging, psychophysiology, psychopharmacology, developmental psychology, clinical assessment, intervention and epidemiology. CART was established with an National Institutes of Health (NIH) STAART Center grant in 2003 and became an NIH Autism Center of Excellence (ACE) Center in 2007 and an ACE Network in 2008. Current ACE research projects, along with other CART and affiliated projects, are listed below. CART also awards pilot grant funds.
Two faculty members in the David Geffen School of Medicine – Daniel H. Geschwind, M.D., Ph.D., and Barbara Vickrey, M.D., M.P.H. – have been elected to membership in the Institute of Medicine (IOM) of the National Academy of Sciences. Membership in the Institute of Medicine is one of the highest honors conferred in the Health Sciences in the U.S. and internationally.
Dr. Geschwind is the Gordon and Virginia MacDonald Distinguished Professor, departments of neurology, psychiatry and human genetics and director, program in neurogenetics and Center for Autism Research and Treatment, Semel Institute. His studies include the development of novel methods as well as applications to study the normal brain and its disorders using advanced genetic techniques. He has evaluated the genetic aspects of normal language and disorders that affect it such as autism, and has also studied degenerative disorders of the brain such as dementias.
New Scientist and MyHealthNewsDaily.com reported Sept. 29; Medscape Today reported Sept. 26; and PsychCentral reported Sept. 25 on a Neuron study by Dr. Daniel Geschwind discovering that a key signaling pathway plays an important role in a common form of early-onset dementia, and may offer a potential target for treatment.